KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Interest Expenses for 7 consecutive years, with $69.3 million as the latest value for Q1 2026.

  • For Q1 2026, Interest Expenses rose 18.83% year-over-year to $69.3 million; the TTM value through Mar 2026 reached $219.3 million, up 33.0%, while the annual FY2025 figure was $252.6 million, 78.08% up from the prior year.
  • Interest Expenses hit $69.3 million in Q1 2026 for Alnylam Pharmaceuticals, up from $65.4 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $69.3 million in Q1 2026 and bottomed at $29.0 million in Q1 2023.
  • Average Interest Expenses over 5 years is $41.0 million, with a median of $39.0 million recorded in 2024.
  • Year-over-year, Interest Expenses tumbled 31.65% in 2023 and then skyrocketed 67.82% in 2025.
  • Alnylam Pharmaceuticals' Interest Expenses stood at $29.9 million in 2022, then rose by 4.76% to $31.3 million in 2023, then grew by 24.36% to $39.0 million in 2024, then skyrocketed by 67.82% to $65.4 million in 2025, then grew by 5.94% to $69.3 million in 2026.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $69.3 million, $65.4 million, and $44.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.